Cerevance announced positive Phase 1 trial results for CVN293, a novel KCNK13 inhibitor targeting neuroinflammation. The drug was well-tolerated in healthy adults and demonstrated robust brain penetration. These findings were presented at the American Academy of Neurology (AAN) 2025 Annual Meeting.
This successful Phase 1 trial is a crucial step for Cerevance, validating the potential of KCNK13 inhibition as a therapeutic strategy for neurodegenerative diseases driven by neuroinflammation. This is particularly important given the current lack of effective treatments for many of these conditions, offering hope for patients suffering from debilitating illnesses like Alzheimer’s and Parkinson’s disease. Furthermore, the confirmation of brain penetration strengthens the rationale for pursuing this mechanism in neurological disorders.
The Phase 1 study, encompassing single and multiple ascending doses, enrolled 72 healthy adult volunteers. Importantly, all participants completed the trial with no severe or dose-limiting adverse events reported. Plasma exposure to CVN293 increased proportionally with dose, and cerebrospinal fluid analysis confirmed substantial drug levels in the central nervous system. Cerevance also highlighted its NETSseq platform and solengepras, a non-dopaminergic Parkinson’s disease treatment, at AAN.
The positive safety and pharmacokinetic profile of CVN293 pave the way for future clinical trials in patients with neuroinflammatory diseases. This development positions Cerevance to potentially address a significant unmet medical need and advances the field towards novel treatments for neurodegenerative disorders. The company’s pipeline, including solengepras, further strengthens its position in developing innovative therapies for neurological conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
